医学
靶向治疗
叙述性评论
临床试验
肿瘤科
转化研究
放射治疗
生物信息学
医学物理学
剂量学
阿尔法(金融)
随机对照试验
生物标志物
内科学
总体生存率
前列腺癌
放射性核素治疗
临床研究设计
精密医学
梅德林
计算生物学
癌症研究
广谱
作者
Qimin Li,谢建,Fei Chen,Laixiang Li,杨传盛
标识
DOI:10.3389/fonc.2026.2007300
摘要
Targeted alpha therapy (TAT) delivers high-linear-energy-transfer radiation over a few cell diameters and is being explored for resistant and microscopic solid-tumor disease. This targeted narrative review evaluates alpha-emitting platforms and clinical evidence by tumor type and development stage, with a focused literature update through 12 October 2026. Unlike broader radiochemistry-centered reviews, we place approved, randomized, early-phase, observational, and preclinical findings in separate evidence tiers. Radium-223 dichloride has randomized survival evidence in symptomatic bone-metastatic castration-resistant prostate cancer, whereas molecularly targeted actinium-225, lead-212, astatine-211, and thorium-227 agents remain investigational in the indications discussed. Updated examples include the 2026 ACTION-1 actinium-225-DOTATATE dosimetry substudy, the 2026 first-in-human astatine-211-MABG study, 2025 lead-212-DOTAMTATE phase II disclosures, and a negative 2025 mesothelin-targeted thorium-227 study. Quantitative outcomes are reported with their study design and limitations rather than interpreted as indirect head-to-head comparisons. Major barriers include isotope supply, incomplete daughter retention, salivary, marrow, and kidney toxicity, spatially heterogeneous target uptake, and uncertainty in patient-specific microdosimetry. We propose practical, imaging-led selection and a priority-ranked translational roadmap.
科研通智能强力驱动
Strongly Powered by AbleSci AI